NCT06923891View on ClinicalTrials.gov

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

172

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

November 30, 2026

Conditions

Schizophrenia

Interventions

DRUG

Xanomeline/Trospium

Xanomeline/Trospium (titrated dose)

Trial Locations (1)

77407

Clinical Site, Richmond

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Vanguard Research Group

OTHER

NCT06923891 - An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients | Biotech Hunter | Biotech Hunter